Telix Pharmaceuticals Limited (ASX:TLX) FDA Accepts BLA for TLX250-CDx
Telix Pharmaceuticals (ASX:TLX) announces FDA acceptance of BLA for TLX250-CDx, targeting kidney cancer imaging with a planned U.S. launch in 2025.
Category: Healthcare
OncoSil Medical Ltd (ASX:OSL) Delivers Key Milestones and Financial Growth in H1 2025
OncoSil Medical Ltd (ASX:OSL) achieves significant clinical and financial milestones, expanding its global presence and enhancing its financial position in H1 2025.
Acrux (ASX:ACR) Reports A$20M Revenue and Announces US Product Launches
Acrux (ASX:ACR) reports A$20 million revenue for FY23-FY24 and announces new US product launches, bolstering its presence in the pharmaceutical market.
Archer Materials Limited (ASX:AXE) Enhances Biochip Feasibility and Advances Development Roadmap
Archer Materials Limited (ASX:AXE) improves Biochip’s potassium detection accuracy, advances to human blood testing, and plans regulatory engagements.
Dimerix Limited (ASX:DXB) Reports Half-Year Financial Results
Dimerix Limited (ASX:DXB) reports a 113% revenue increase in the half-year ended December 2024, alongside a 93% rise in losses.
4DMedical (ASX:4DX) Gains Regulatory Approval for CT LVAS™ in Canada
4DMedical (ASX:4DX) secures Canadian approval for CT LVAS™, expanding its respiratory imaging portfolio and market reach.
4DMedical Limited (ASX:4DX) Launches Share Purchase Plan
4DMedical Limited (ASX:4DX) launches a Share Purchase Plan, enabling shareholders to buy up to $30,000 in new shares without fees.
Telix Pharmaceuticals Limited (ASX:TLX) Changes Reporting Currency to USD
Telix Pharmaceuticals Limited (ASX:TLX) will change its reporting currency from AUD to USD effective 1 January 2025, aligning financial reports with its US-based operations.
Noxopharm Limited (ASX:NOX) Reports FY2025 Half Year Results
Noxopharm Limited (ASX:NOX) reports a 50.5% reduction in half-year losses and advances its clinical trials and strategic partnerships.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Rare Pediatric Disease Designation
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.